However, treatment decision remains challenging, especially among ER-positive, HER2-negative invasive breast cancers that are often less responsive to chemotherapy and may derive more clinical benefit from endocrine therapy alone. This evidence concerns the gene ERBB2 and invasive breast carcinoma.